Clinical trial
Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver…
NCT00242502 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00242502 |
|---|---|
| Title | Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery |
| Official title | A Phase II Study of the Combination of Bevacizumab and Erlotinib in Patients With Unresectable Hepatocellular Carcinoma |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hepatocellular Carcinoma, Liver Cancer |
| Intervention type | Drug |
| Interventions | Bevacizumab (Avastin), Erlotinib |
| Enrollment | 62 |
| Start date | Oct 1, 2005 |
| Primary completion | Oct 1, 2011 |
| Completion | Oct 1, 2011 |
| First posted | Oct 20, 2005 |
| Last update posted | May 6, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: